(Total Views: 674)
Posted On: 10/06/2024 9:42:52 AM
Post# of 154142
I think the board here should understand when trying to size up the prospects of Leronlimab in the upcoming MSS CRC study when reflecting on the bevacizumab plus TAS-102 OHM20 posted, that the later under
NCT04737187 does not have an inclusion (or exclusion) criteria for MSS status but the Leronlimab study does. A reminder most on this board already understand, current regimens don’t effectively treat the 85% of CRC represented by MSS status and the odds of survival are markedly different:
“ Compared to MSS CRCs, patients with MSI have a 40% reduced risk of death and recurrence and the benefit in OS is independent of other prognostic factors according to multivariate analysis and the receipt of chemotherapy.”
https://ar.iiarjournals.org/content/39/12/643...emotherapy.
This is a very important trial for that reason and considering what we understand about Leronlimab’s mechanism of action the trial has a decent shot at success. If this proves out it will send shockwaves through the oncology world and give the many patients with negligible hope a new reason to be optimistic. For this reason solid, undeniable data from this trial should nudge the FDA toward breakthrough therapy designation and service Dr Jay’s goal to get the drug to market as quickly as possible.
NCT04737187 does not have an inclusion (or exclusion) criteria for MSS status but the Leronlimab study does. A reminder most on this board already understand, current regimens don’t effectively treat the 85% of CRC represented by MSS status and the odds of survival are markedly different:
“ Compared to MSS CRCs, patients with MSI have a 40% reduced risk of death and recurrence and the benefit in OS is independent of other prognostic factors according to multivariate analysis and the receipt of chemotherapy.”
https://ar.iiarjournals.org/content/39/12/643...emotherapy.
This is a very important trial for that reason and considering what we understand about Leronlimab’s mechanism of action the trial has a decent shot at success. If this proves out it will send shockwaves through the oncology world and give the many patients with negligible hope a new reason to be optimistic. For this reason solid, undeniable data from this trial should nudge the FDA toward breakthrough therapy designation and service Dr Jay’s goal to get the drug to market as quickly as possible.
(26)
(0)
